Cardiovascular Systems CSII shares rose 47% to $19.58 in early premarket trade after Abbott ABT agreed to buy the company for $890 million, or $20 per share. CSI is a leader in devices for atherectomy, a minimally invasive treatment for plaque build-up in arteries. Abbott said the deal is neutral to its recently issued 2023 ongoing earnings per share guidance.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.